A meta-analysis conducted in 2023 showed that the GSTP1 rs1695 polymorphism was significantly correlated with platinum-induced toxicities; it was concluded that personalized chemotherapy based on these polymorphisms could be considered for cancer patients in the future [208]. This evidence concerns the gene GSTP1 and cancer.